key: cord-0731235-ljyf2428
authors: Isgro, Graziella; Yusuff, Hakeem O.; Zochios, Vasileios
title: The Right Ventricle in COVID-19 Lung Injury: Proposed Mechanisms, Management and Research Gaps
date: 2021-01-15
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.01.014
sha: d1a7a97da79771aadc9d6e99b6d0f2e80da65e25
doc_id: 731235
cord_uid: ljyf2428

nan

protein") to angiotensin converting enzyme 2(ACE 2) receptors expressed not only by vascular endothelial cells but also by epithelial cells in the lungs, heart, kidney and intestine. 12 The entry of the virus contributes to inflammation and damage of the endothelial cells causing release of plasminogen activator which explains the high D-dimer concentration in severe cases, and prothrombotic mediators primarily factor VIIIc and von Willebrand factor multimers. The latter mediates the consequent deposit of microvascular thrombi, especially in affected pulmonary vessels. [13] [14] [15] The simultaneous presence of vascular inflammation and coagulopathy might explain the high incidence of thromboembolic complications in patients with COVID-19. Similarly, markers of coagulopathy, such as D-dimer, have been closely associated with thrombotic complications and increased mortality. 13, [16] [17] [18] Pulmonary hemodynamic alteration created by intravascular micro-thrombosis and vasoconstriction secondary to hypoxia may cause acute pulmonary hypertension resulting in suboptimal RV-pulmonary arterial (PA) coupling (a determinant of RV systolic pressure and RV stroke volume) and secondary RV dysfunction (RVD) in patients with COVID-19 even at the early stages of the disease. 19, 20 In the critically ill COVID-19 patient, adaptation of the RV to increased loading conditions may be limited due to systemic hypotension and inflammation, and as a result RVD can progress to RV failure (RVF). 19, 20 Myocardial Injury in Early reports from China identified the presence of elevated cardiac biomarkers in a considerable proportion of patients with COVID-19. 3, 21 Specifically, raised troponin and brain natriuretic peptide (BNP) levels were shown to be correlated with elevation in D-Dimer and were predictive of poor outcomes. 22 Recent studies report cardiac complications such as acute coronary syndromes, cardiac arrhythmias, myocarditis, pericarditis and heart failure in nearly 20% of patients with COVID-19, and they are associated with an increased risk of death. 21 It remains however unclear whether RVD in the presence of myocardial complications without micro-or macrovascular pulmonary thrombosis is caused by RV ischemia, RV-PA uncoupling or severe inflammation. 23 

Although severe COVID-19 infection shares many laboratory and clinical features of severe bacterial sepsis, up to 80% of patients with COVID-19 may have no microbiological evidence of bacteremia or fungemia. 24, 25 However, superadded intensive care unit (ICU)acquired infections can potentially complicate the clinical course of COVID-19 critically ill patients leading to multiple organ dysfunction and death. Can viral sepsis explain RVD in COVID-19 "lung injured" patients? In theory, isolated RVD in patients with sepsis reflects endothelial dysfunction, altered vasoreactivity, acute increase in pulmonary vascular resistance (PVR) despite systemic vasodilatation, and inability of the RV to adapt to physiological stress, and it is associated with long-term mortality. [26] [27] [28] This mechanistic link, however is yet to be proven in prospective COVID-19 studies.

Hypoxemia and/or hypercapnia with or without acidemia in COVID-19 patients with severe acute respiratory failure may cause or exacerbate pulmonary vasoconstriction resulting in increased (even modest) RV afterload, RV-PA uncoupling and RVD with potential for reduced cardiovascular performance. 23, 29, 30 "Injurious" invasive ventilation in COVID-19 patients with refractory hypoxemia and/or hypercapnia in extremes of tidal volume, high transpulmonary (alveolar-pleural pressure) and driving (plateau pressuretotal positive end-expiratory pressure (PEEP)) pressures, and excessive PEEP causing non-physiological lung "stress" and "strain" and alveolar overdistension may result in alveolar vessel collapse and acute increase in PVR leading to RVD. [31] [32] [33] In patients with acute respiratory distress syndrome (ARDS), one clinical and three physiological parameters have been identified as statistically significant predictors of RVD: lower respiratory tract infection as a cause of pulmonary ARDS; ratio of arterial oxygen partial pressure (P a O 2 ) to fractional inspired oxygen (F i O 2 ) ratio < 150 mm Hg, (3) P a CO 2 > 48 mm Hg; and driving pressure > 18 cm H 2 O. 34 An RVD score > 2 is associated with a 19% incidence of RVD (34%, and 74% for risk scores of 3 and 4, respectively). Although this scoring system makes physiological sense it has not been validated in COVID-19 patient populations yet. 34 It highlights, however, the importance of "RV-protective" ventilation strategies in patients with "injured" lungs and need for early echocardiography.

Although diagnostic approach to suspected RVD should be multi-modal, echocardiography remains the cornerstone bedside tool to assess cardiac function and pathology. A large prospective echocardiography study of COVID-19 patients showed that whilst RV dilatation with or without dysfunction was the most frequent abnormality (39%) followed by left ventricular (LV) diastolic dysfunction (16%), LV systolic impairment was uncommon.

Twenty per cent of patients in that cohort experienced a deterioration of the RV parameters probably secondary to increased pulmonary vascular pressure contributing to increased RV afterload. 6 Similar results were demonstrated in a more recent retrospective echocardiography study that evaluated 110 patients. 35 In that cohort, although LV function and size were normal, RV dilatation was present in 31% of patients. More than half (66%) of the latter group had RV hypokinesia and 21% had moderate or severe tricuspid regurgitation. 35 In another small retrospective study which included invasively ventilated patients with COVID-19, 42.2% of which received veno-venous extracorporeal membrane oxygenation (VVECMO), found radial RV impairment with sparing of longitudinal function to be the dominant echocardiographic phenotype. 36 Two-dimensional speckle tracking echocardiography has also been used to evaluate RV function in COVID-19 patients and interestingly RV longitudinal strain was identified as a powerful predictor of mortality. 37 There is a clear need for large-scale prospective echocardiography data in COVID-19 patients at risk of RVD in order to identify early markers of dysfunction, characterize the natural history of RVD and monitor response to therapies.

The principles of RVD management in COVID-19 patients should follow standard general RVD management including optimization of RV preload, increase in RV contractility and reduction in pulmonary vascular resistance and RV afterload leading to optimal RV-PA coupling. 38 Importantly, "RV-protective" strategies should be implemented early and rescue specific therapies such as ECMO should be considered in refractory selected cases in centres with expertise in use of ECMO for cardiorespiratory support. 38

The debate on how to ventilate the COVID-19 patient is still on going. A number of interrelated editorials have suggested that a subset of patients with COVID-19 induced ARDS have an unusual physiological phenotype ("L-type" phenotype), with low elastance, low lung weight, and low recruitability. Based on these physiological results the authors suggested that high levels of PEEP may be detrimental, and that prone positioning is unlikely to be beneficial. 39 A recent study suggested that patients with early severe COVID-19 pneumonitis do not differ in their response to high PEEP and prone positioning from classic ARDS, and should therefore be ventilated according to established ARDS principles and regimens. 40 Protective ventilation in ARDS reduces RVD and specifically a plateau pressure of less than 26-28 cm H 2 O is associated with lower incidence of RVD. Despite the possible presence of distinct phenotypes of COVID-19 patients with severe respiratory failure, there is currently lack of data relating to the best "RV-protective" ventilatory strategies. 41 It would stand to reason that in patients with or at risk of RVD, a "RV-protective" ventilatory strategy comprises: 42-44 1) Low "stress" ventilation (plateau pressure< 27cm H 2 O and driving pressure < 18cmH 2 O); 2) P a CO 2 < 48mmHg; 3) P a O 2 :F i O 2 > 150 mm Hg; 4) consideration of driving pressure-guided PEEP titration (aiming for a PEEP range associated with lowest driving pressure); and 5) consideration of echocardiography use (transthoracic or transesophageal) during PEEP titration to monitor RV loading conditions. [42] [43] [44] 

Prone ventilation has the potential to recruit collapsed alveoli, reduce tidal hyperinflation, alveolar cyclic recruitment/de-recruitment and ventilator-induced lung injury known to exacerbate RVD. [45] [46] [47] Correction of hypoxemia and hypercapnia reduces pulmonary vasoconstriction thus unloading the RV in ARDS. [45] [46] [47] [48] So far, no data is available on the effects of prone positioning on RVD (assessed by echocardiography) and pulmonary circulation in COVID-19 patients. 48 Given the RVprotective effect of prone positioning, it could be hypothesized that COVID-19 ventilated patients with RVD would potentially benefit from early proning irrespective of the degree of hypoxemia; however, this notion needs to be tested in prospective studies.

Although current evidence does not support routine use of pulmonary vasodilators and in particular inhaled nitric oxide (iNO) in patients with ARDS, as it does not confer survival benefit, its use as rescue therapy has been recommended by recently published guidelines on management of the acutely ill COVID-19 patients with severe respiratory failure. 49 Pulmonary vasodilators could theoretically be beneficial in selected patients through an improvement in ventilation-perfusion matching through their vasodilatory effect and subsequent reduction in pulmonary arterial pressure and RV afterload. 50 In a recent case report, iNO was administered to a patient with RVD and COVID-19 pneumonitis requiring VVECMO to improve recirculation fraction by reducing pulmonary hypertension, RV afterload and tricuspid regurgitation. 49 In this case iNO successfully offloaded a pressure overloaded RV and reduced the severity of tricuspid regurgitation and recirculation 12 hours after initiation of therapy. 49 The role of other pulmonary vasodilators such as inhaled prostanoids and analogues (prostacyclin and iloprost respectively), phosphodiesterase-5 inhibitors (sildenafil) in COVID-19 is unknown and should be used with caution given the lack of data and potential for worsening of hypoxemia and shunt fraction. 38, 51 Future research should focus on the potential benefit of early use of pulmonary vasodilators and inodilators (eg phosphodiesterase-3 inhibitors) in COVID-19 critically ill patients with RVD confirmed by echocardiography or right heart catheterization.

Veno-venous ECMO improves hypoxemia and reduces hypercapnia, facilitating a "lung rest" strategy with tight control of driving pressure and ultimately can decrease pulmonary vasoconstriction and right ventricular afterload. 52 Contrary to preliminary results from early studies that indicated dismal outcomes in COVID-19 patients supported with VV ECMO, recent studies have demonstrated an estimated less than 40% probability of 60-day mortality, similar to those treated with ECMO in the ECMO to Rescue Severe Lung Injury in Severe ARDS (EOLIA) trial. 52, 53 Due to the significant incidence of RV dilatation and dysfunction in severe COVID-19, traditional VV ECMO may not be effective and a change in strategy to support the RV may be required. This may be achieved by either veno -arterial (VA), veno-venous and arterial (V-VA) or veno-pulmonary arterial (V-PA) ECMO. [53] [54] [55] The conventional VA ECMO mode has obvious hemodynamic advantages (RV unloading, peripheral oxygenation, temperature control) but carries several disadvantages. For example, patients may present with an increased LV afterload leading to insufficient unloading and requiring an additional LV venting device especially if there is co-existing LV impairment. A recent observational cohort study of the extracorporeal life support (ELSO) database demonstrated increased mortality associated with the use of VA ECMO in COVID-19 patients. 53 Cardiac ECMO however, was utilized in a small proportion of patients only (3%) and this may suggest that it was provided as salvage therapy to patients at the extreme end of disease severity.

Veno-venous and arterial ECMO has the advantage of providing respiratory support and biventricular cardiac support. The RV is decompressed and the RV afterload is reduced due to oxygenated and decarboxylated blood flowing through the pulmonary circulation. There is currently paucity of data to suggest this strategy is beneficial in COVID-19 patients with RVD.

A direct PA cannulation approach accessed either surgically or percutaneously to facilitate V-PA ECMO has been suggested to unload and support the failing RV whilst providing respiratory support. 54 A recent study documents the use of a single access, dual stage cannula in a group of COVID-19 patients requiring VVECMO support. This approach demonstrated multiple advantages including direct pulmonary artery flow, negligible recirculation, early extubation and mobilization whilst on ECMO support, with a survival rate of 73%. 55 This might be the way forward to support the RV in COVID-19 patients with RVD and refractory severe respiratory failure, requiring extracorporeal support who fail to respond to pharmacological and ventilatory "RV-protective" measures. However, this was a single centre study and therefore larger multi-centre trials would be required to demonstrate that these outcomes can be replicated. In addition, strategies to simplify and improve access to safe percutaneous PA cannulation would facilitate more widespread use if this technique.

The RV is intricately connected to the clinical syndrome resulting from SARS COV2 infection. In less severe states the RV is able to compensate to ensure normal physiology, however in decompensated states this leads to severe manifestations of the disease. As a result, RVD is associated with worse outcomes in the context of COVID-19 disease. 35, 56 This remains very difficult to manage and future research should be directed at ways of protecting the RV before dysfunction develops, monitoring of RVD and response to treatment, echocardiographic and hemodynamic RVD phenotyping and effective management of established RV failure in patients with severe COVID-19 disease.

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

COVID-19 and the cardiovascular system

The overlooked chamber in coronavirus disease 2019

Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Recommendations for chamber quantification: a report from the American Society of Echocardiography"s Guidelines and Standards Committee and the Chamber Quantification Writing Group

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Hematologic parameters in patients with COVID-19 infection

Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease

COVID-19 and ECMO: An Unhappy Marriage of Endothelial Dysfunction and Hemostatic Derangements

Covid:19 A complex multisystem disorder

Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19

Patients Requiring Extracorporeal Membrane Oxygenation

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Hypoxic pulmonary vasoconstriction

Diagnostic workup, etiologies and management of acute right ventricle failure: A state-of-the-art paper

Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms

Incidence and determinants of highsensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients

Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS

Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study

Epidemiology and immune pathogenesis of viral sepsis

Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: an 8-year historical cohort study

Impact of Right Ventricular Dysfunction on Short-and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients. Chest 2020 In press

Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality

Effective arterial elastance as an index of pulmonary vascular load

Right ventriculoarterial coupling in acute respiratory distress syndrome (ARDS) and expected benefits of CO2 removal therapy

Respiratory mechanics and lung stress/strain in children with acute respiratory distress syndrome

Regional distribution of gas and tissue in acute respiratory distress syndrome. I. Consequences for lung morphology: CT Scan ARDS Group

Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements

Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact

Right Ventricular Dilation in Hospitalized Patients With COVID-19 Infection

Right ventricular dysfunction in critically ill COVID-19 ARDS

Prognostic Value of Right Ventricular Longitudinal Strain in Patients With COVID-19

Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Evaluation of PEEP and prone positioning in early COVID-19 ARDS

Phenotypes of severe COVID-19 ARDS receiving extracorporeal membrane oxygenation

Rationale and description of right ventricle-protective ventilation in ARDS

PEEP Titration to Minimize Driving Pressure in Subjects With ARDS: A Prospective Physiological Study

Should we titrate ventilation based on driving pressure? Maybe not in the way we would expect

Adverse Heart-Lung Interactions in Ventilator-induced Lung Injury

Prone position-induced improvement in gas exchange does not predict improved survival in the acute respiratory distress syndrome

Mechanisms of the effects of prone positioning in acute respiratory distress syndrome

Protecting the Right Ventricle in ARDS: The Role of Prone Ventilation

Nitric Oxide Ventilation Improves Recirculation and Right Ventricular Function During Veno-Venous Extracorporeal Membrane Oxygenation in a COVID-19 Patient

Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome

Sildenafil for pulmonary hypertension in ARDS: a new pleasant effect?

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Pulmonary artery cannulation to enhance extracorporeal membrane oxygenation management in acute cardiac failure

Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure

Impact of Right Ventricular Dysfunction on Mortality in Patients Hospitalized with COVID-19 according to Race